Background: Adenocarcinoma is the most frequent pathological type of stomach cancer. Hodgkin’s lymphoma is a lymphoproliferative disease arising from lymphoid tissue which is characterized by Reed-Sternberg cells. Synchronous occurrence of these two malignancies has not been reported in the English literature so far. Case: Here we present a 52-year-old male complaining of epigastric pain and fever diagnosed as stomach adenocarcinoma and Hodgkin’s lymphoma. Conclusion: It is thought that this case is the first of a synchronous stomach adenocarcinoma and Hodgkin’s lymphoma encountered in the English literature. It should be kept in mind that second malignancies can be seen in mass lesions in patients diagnosed with cancer.

Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827–841.
Skorecki K, Green J, Brenner BM: Chronic renal failure; in Braunwald E, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine. London, McGraw-Hill, 2001, pp 1551–1561.
Hamaloglu E, Topaloglu S, Ozdemir A, Ozenc A: Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: a review of the literature. World J Gastroenterol 2006;12:3564–3574.
Park SH, Rha SY, Shim DK, Rho HJ, Yoo NC, Kim JH, Roh JK, Yang WI, Noh SH, Min JS, Kim BS, Chung HC: An unusual case of gastric carcinoma with synchronous non-Hodgkin’s lymphoma. Yonsei Med J 1998;39:463–467.
Gore R: Gastrointestinal cancer. Radiol Clin North Am 1997;35:295–310.
Huang XE, Tajima K, Hamajima N, Kodera Y, Yamamura Y, Xiang J, Tominaga S, Tokudome S: Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer. Nutr Cancer 2000;38:30–36.
Fenogilo-Preiser C, Carneiro F, Correa P: Gastric carcinoma; in Hamilton S, Aaltonin L (eds): Pathology and Genetics. Tumors of the Digestive System. Lyon, Lyon Press, 2000, vol 1, pp 37–52.
Moertel CG: Multiple primary malignant neoplasms. Historical perspectives. Cancer 1977;40:1786–1792.
Mulvilhill JJ, McKeen EA: Genetics of multiple primary tumors. A clinical etiologic approach illustrated by three patients. Cancer 1977;40:1812–1820.
Berg JW, Schottenfeld D: Multiple primary cancers at Memorial Hospital, 1949–1962. Cancer 1977;40:1801–1805.
Hoar SK, Wilson JK, Blot WJ: Second Cancer following Cancer of the Digestive System in Connecticut 1935–1982. Washington, NCI Monograph, 1985, vol 68, pp 49–64.
Arseneau JC, Canellos GP, Johnson R, De Vita VT Jr: Risk of new cancers in patients with Hodgkin’s disease. Cancer 1977;40:1912–1916.
Warren S, Gates O: Lung cancer and metastasis. Arch Pathol 1964;78:467–473.
Lundegårdh G, Hansson LE, Nyrén O, Adami HO, Krusemo UB: The risk of gastrointestinal and other primary malignant disease following gastric cancer. Acta Oncol 1991;30:1–6.
Dinis-Ribeiro M, Lomba-Viana H, Silva R, Moreira-Dias L, Lomba-Viana R: Associated primary tumors in patients with gastric cancer. J Clin Gastroenterol 2002;34:533–535.
Ikeda Y, Saku M, Kawanaka H, Nonaka M, Yoshida K: Features of second primary cancer in patients with gastric cancer. Oncology 2003;65:113–117.
Thomas RK, Re D, Wolf J, Diehl V: Part I: Hodgkin’s lymphoma – molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004;5:11–18.
Ekert H: Chemotherapy for Hodgkin’s disease. N Engl J Med 2003;349:1186–1187.
Gupta T, Sanghavi V, Laskar S: Radiotherapy for advanced Hodgkin’s disease. N Engl J Med 2003;349:1187–1188.
Diehl V, Thomas RK, Re D: Part II: Hodgkin’s lymphoma – diagnosis and treatment. Lancet Oncol 2004;5:19–26.
Rubiales AS, Martinez G, Aller JL, Roig V, del Valle ML: Synchronous diagnosis of small-cell lung cancer and Hodgkin lymphoma. An Med Interna 2006;23:301–302.
Quilon JM, Day S, Lasker JC: Synchronous tumors: Hodgkin disease presenting in mesenteric lymph nodes from a right hemicolectomy for colon carcinoma. South Med J 2004;97:1133–1135.
Prabhash K, Babu KG, Balu S, Haritha C, Bapsy PP: Hodgkin’s disease and pilocytic astrocytoma – a synchronous presentation. J Assoc Physicians India 2003;51:833–834.
Suh YK, Shin SS, Koo CH: Synchronous Hodgkin’s disease and granulocytic sarcoma with no prior therapy. Hum Pathol 1996;27:1103–1106.
Adnan E, Nicholas S, Madras R, Ashraf AM: Synchronous Hodgkin’s disease and non-Hodgkin’s lymphoma. Acta Oncol 1996;35:755–757.
Cutuli BF, Cribier B, Giron C: Synchronous Hodgkin disease and mycosis fungoides. Presse Med 1994;23:1228.
Vukelja SJ, Krishnan J, Ward FT, Redmond J 3rd: Synchronous Hodgkin’s disease and myelofibrosis terminating with granulocytic sarcoma and acute megakaryocytic leukemia. South Med J 1990;83:1317–1320.
Stante M, Salvini C, De Giorgi V, Carli P: Multiple synchronous pigmented basal cell carcinomas following radiotherapy for Hodgkin’s disease. Int J Dermatol 2002;41:208–211.
Lovell MO, Valente PT: Unique collision of Hodgkin lymphoma and adenosquamous carcinoma in the uterine cervix: synchronous malignant neoplasms of the cervix. J Low Genit Tract Dis 2003;7:307–311.
Gerl A, Clemm C, Salat C, Mittermuller J, Bomfleur W, Wilmanns W: Testicular cancer and Hodgkin disease in the same patient. Cancer 1993;71:2838–2840.
Cervin JR, Silverman JF, Loggie BW, Geisinger KR: Virchow’s node revisited. Analysis with clinicopathologic correlation of 152 fine-needle aspiration biopsies of supraclavicular lymph. Arch Pathol Lab Med 1995;119:727–730.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.